The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis

por Egeberg, A., Gisondi, P., Carrascosa, J.M., Warren, R.B., Mrowietz, U.
Publicado 2020

A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF

por Friis Petersen, J, Løkkegaard, E, Andersen, L F, Torp, K, Egeberg, A, Hedegaard, L, Nysom, D, Nyboe Andersen, A
Publicado 2019

Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians

por van Ee, I., Deprez, E., Egeberg, A., Augustin, M., Conrad, C., Corazza, V., Donati, L., Lambert, J., Lăpădatu, R., Meyer, A., Paul, C., Penzer‐Hick, R., Stephen, K., van der Zon, J., Bewley, A.
Publicado 2021

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2

por Fernandez, A.P., Dauden, E., Gerdes, S., Lebwohl, M.G., Menter, M.A., Leonardi, C.L., Gooderham, M., Gebauer, K., Tada, Y., Lacour, J.P., Bianchi, L., Egeberg, A., Pau‐Charles, I., Mendelsohn, A.M., Rozzo, S.J., Mehta, N.N.
Publicado 2022